Sep 23 |
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
|
Sep 16 |
We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth
|
Sep 4 |
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
|
Aug 27 |
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?
|
Aug 8 |
Context Therapeutics GAAP EPS of -$0.04
|
Aug 7 |
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
|
Aug 6 |
Context Therapeutics Inc.'s (NASDAQ:CNTX) top owners are individual investors with 52% stake, while 30% is held by private equity firms
|
Aug 1 |
Context Therapeutics appoints Claudio Ullmann as chief medical officer
|
Aug 1 |
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
|
Jul 10 |
Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline
|